Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors (Q36181360)

12 August 2017

Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors (English)

1 reference

12 August 2017

Kilby JM

1

1 reference

PubMed ID

15992142

12 August 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

8

1 reference

12 August 2017

8

1 reference

12 August 2017

1157-1170

1 reference

HIV infection is blocked in vitro by recombinant soluble CD4.

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Cross-clade inhibition of human immunodeficiency virus type 1 primary isolates by monoclonal anti-CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Dextran sulfate is poorly absorbed after oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Inhibition of HIV-1 infection by the beta-chemokine MDC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A general model for the transmembrane proteins of HIV and other retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Structural rearrangements in the transmembrane glycoprotein after receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A spring-loaded mechanism for the conformational change of influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

HIV blocked by chemokine antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.8.1157

10.1517/13543784.8.8.1157

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15992142